|
|
Only ongoing agreements and public funds are listed |
| Feb.2000
|
Founded Renascience Inc. as an academic bio-venture company in Kanagawa, Japan |
| Oct.2016
|
License agreement with Eirion Therapeutics, Inc., USA for dermatological indications |
| Dec.2019
|
Adopted as an AMED’s Cyclic Innovation for Clinical Empowerment (CiCLE) program(Project for premenstrual syndrome/premenstrual dysphoric mood disorder) |
| Dec.2019
|
Concluded an option agreement with ASKA Pharmaceutical Co., Ltd. for a license agreement of pyridoxamine on premenstrual syndrome / premenstrual dysphoric mood disorder |
| May.2020
|
License agreement with Global Medical Device Company for Ultrafine Endoscopes |
| Jul.2020
|
Signed an agreement with CHEST M.I., Inc. for the joint development and commercialization of respiratory AI solutions |
| Dec.2020
|
Initiated a PhaseⅡ investigator-initiated clinical study on premenstrual syndrome/premenstrual dysphoric mood disorder |
| Dec.2020
|
Option agreement with Daiichi Sankyo Co., Ltd. for the treatment of respiratory diseases including COVID-19 pneumonia and other lung injuries |
| May.2021
|
Collaboration agreement with Nipro Corporation for the development of chronic dialysis support system using artificial intelligence (AI) |
| May.2021
|
Selected as AMED Translational Research Program, seeds C (Malignant melanoma project) |
| Jul.2021
|
Initiated a PhaseⅡ investigator-initiated clinical study on malignant melanoma |
| Sep.2021
|
Listed on the Tokyo Stock Exchange Mothers market (current Growth market, securities code: 4889) |
| Jan.2022
|
Open Tohoku University Renascience Open Innovation Labo (TREx) |
| Mar.2022
|
Adopted as a sharing organization in an AMED’s Research program for Practical Application of Innovative Cancer Medicine (CML project) |
| Apr.2022
|
Adopted as an AMED’s Commercialization Promotion Project for Medical-engineering Collaboration (Support for small and medium-sized enterprises development and commercialization) |
| Jun.2022
|
Transitions from a Company with Corporate Auditors to a Company with an Audit Committee, and Introduction of Executive Officer System |
| Aug.2022
|
Initiation of dosing in a PhaseⅢ study of chronic myeloid leukemia |
| Sep.2022
|
Collaboration Agreement with HI-LEX Corporation and its Subsidiary HI-LEX Medical |
| Nov.2022
|
Memorandum of Understanding with NEC Solution Innovators, Ltd. |
| Dec.2022
|
Regulatory Approval of Ultrafine Disposable Endoscope |
| Feb.2023
|
Adoption of AMED Research on Development of New Medical Devices (AI Project Supporting Chronic Dialysis System) |
| Mar.2023
|
Adoption in AMED Practical Research Program for Intractable Diseases (Systemic Scleroderma Project) |
| Apr.2023
|
Results of Placebo-Controlled, Double-Blind, PhaseⅡ Investigator-Initiated Clinical Trial of RS5614, a PAI-1 Inhibitor, for Novel Coronavirus (SARS-CoV-2) Pneumonia |
| Apr.2023
|
Open Hiroshima University Renascience Open Innovation Labo (HiREx) |
| Jun.2023
|
Collaboration Agreement with Kyoto University and Daiichi Sankyo Company, Limited |
| Jun.2023
|
Comprehensive Collaboration Agreement with NEC Corporation on AI projects |
| Jun.2023
|
Results of PhaseⅡ Investigator-Initiated Clinical Trial to Evaluate the Safety and Efficacy of RS5614 in Combination with Nivolumab for the Treatment of Malignant Melanoma |
| Aug.2023
|
PAI-1 Inhibitor RS5614 Met Primary Endpoint in Phase II Investigator-Initiated Clinical Trial for Unresectable Malignant Melanoma Refractory to Nivolmab |
| Aug.2023
|
Achievement of Enrollment Goal in Phase II Investigator-Initiated Clinical Trial of RS8001 (pyridoxamine) for the Treatment of Patients with Psychiatric Symptoms of Premenstrual Syndrome/Premenstrual Dysphoric Disorder |
| Sep.2023
|
Initiation of Phase II Study for Non-Small Cell Lung Cancer |
| Oct.2023
|
Initiation of Phase II study for interstitial lung disease associated with systemic scleroderma |
| Oct.2023
|
Initiation of Phase II Study for Cutaneous Angiosarcoma |
| Dec.2023
|
Conclusion of Collaboration Agreement with Toray Medical Co., Ltd |
